Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACHIEVE
NCT04994574Completed
- Sponsor
- Yonsei University
- Start
- Aug 2021
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD), sponsored by Yonsei University. Primary endpoint: Maximum oxygen consumption at 4 weeks. Started Aug 2021; status: completed.
02
Drugs
tiotropiumolodaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT04994574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04994574.